Nature Search

Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma

Surbhi Sidana
Andriyana K. Bankova
Judith A. Shizuru
ResearchOpen Access09 Oct 2024
Blood Cancer Journal

Volume: 14, P: 1-10
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma

Circulating tumor DNA (ctDNA) allows genotyping of the tumor in multiple myeloma. Here, the authors show that minimal residual disease (MRD) by ctDNA can be detected after CAR-T therapy correlates with bone marrow-based MRD to track clonal evolution and inform treatment resistance mechanisms.

Hitomi Hosoya
Mia Carleton
David M. Kurtz
ResearchOpen Access20 Feb 2025
Nature Communications

Volume: 16, P: 1-13
Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Sham Mailankody
Jeffrey V. Matous
Shaji K. Kumar
Amendments and Corrections17 Mar 2023
Nature Medicine

Volume: 29, P: 3271
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma

Christopher Lemieux
Lori S. Muffly
Surbhi Sidana
Research11 Aug 2020
Bone Marrow Transplantation

Volume: 56, P: 368-375
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results

Liora M. Schultz
Nikeshan Jeyakumar
Lori Muffly
Research15 Mar 2024
Leukemia

Volume: 38, P: 963-968
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

In an interim phase 1 trial analysis, escalating doses of off-the-shelf allogeneic anti-BCMA CAR T cells, in combination with an anti-CD52 antibody-containing lymphodepletion regimen, were feasible to administer and exhibited an encouraging safety profile in patients with relapsed or refractory multiple myeloma

Sham Mailankody
Jeffrey V. Matous
Shaji K. Kumar
Research23 Jan 2023
Nature Medicine

Volume: 29, P: 422-429
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma

Surbhi Sidana
Hitomi Hosoya
Murali Janakiram
CorrespondenceOpen Access13 Oct 2023
Blood Cancer Journal

Volume: 13, P: 1-5
Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Eli Muchtar
Morie A. Gertz
Angela Dispenzieri
Research22 Nov 2019
Leukemia

Volume: 34, P: 1135-1143
Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis

Nadine Abdallah
Surbhi Sidana
Shaji Kumar
Research09 Jun 2020
Bone Marrow Transplantation

Volume: 55, P: 1297-1304
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis

Surbhi Sidana
Nidhi Tandon
Wilson I. Gonsalves
Research21 Feb 2018
Leukemia

Volume: 32, P: 1421-1426
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis

Surbhi Sidana
Paolo Milani
Shaji K. Kumar
ResearchOpen Access14 Apr 2020
Blood Cancer Journal

Volume: 10, P: 1-8
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse

Surbhi Sidana
Nidhi Tandon
Shaji K. Kumar
Research15 Oct 2018
Leukemia

Volume: 33, P: 730-738
Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

Surbhi Sidana
Nidhi Tandon
Shaji K. Kumar
Research21 Dec 2017
Bone Marrow Transplantation

Volume: 53, P: 326-333
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22.

Jay Y. Spiegel
Shabnum Patel
David B. Miklos
ResearchOpen Access26 Jul 2021
Nature Medicine

Volume: 27, P: 1419-1431
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Danai Dima
Mariola A. Vazquez-Martinez
Leyla Shune
ResearchOpen Access25 Jun 2025
Blood Cancer Journal

Volume: 15, P: 1-9
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Oren Pasvolsky
Danai Dima
Ariel Grajales-Cruz
ResearchOpen Access09 May 2025
Blood Cancer Journal

Volume: 15, P: 1-6
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma

Christopher Lemieux
Lori S. Muffly
Surbhi Sidana
Research23 Jun 2021
Bone Marrow Transplantation

Volume: 56, P: 2664-2671
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Eli Muchtar
Morie A. Gertz
Angela Dispenzieri
Amendments and Corrections29 Jul 2020
Leukemia

Volume: 34, P: 2819
Revisiting complete response in light chain amyloidosis

Surbhi Sidana
Angela Dispenzieri
Shaji K. Kumar
Research26 Nov 2019
Leukemia

Volume: 34, P: 1472-1475
Primary systemic amyloidosis in patients with Waldenström macroglobulinemia

Saurabh Zanwar
Jithma P. Abeykoon
Prashant Kapoor
Research12 Oct 2018
Leukemia

Volume: 33, P: 790-794
The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response

Surbhi Sidana
Nidhi Tandon
Shaji K. Kumar
Research30 Jan 2018
Leukemia

Volume: 32, P: 1243-1246
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Gliceida Galarza Fortuna
Rahul Banerjee
Doris K. Hansen
ResearchOpen Access16 Oct 2024
Blood Cancer Journal

Volume: 14, P: 1-8
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Christopher J. Ferreri
Michelle A. T. Hildebrandt
Omar Alexis Castaneda Puglianini
ResearchOpen Access09 Aug 2023
Blood Cancer Journal

Volume: 13, P: 1-9
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

Aimaz Afrough
Hamza Hashmi
Yi Lin
CorrespondenceOpen Access12 Apr 2024
Blood Cancer Journal

Volume: 14, P: 1-5
IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

Surbhi Sidana
Daniel P. Larson
Morie A. Gertz
Research28 Nov 2019
Leukemia

Volume: 34, P: 1373-1382
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Luciano J. Costa
Benjamin A. Derman
Bruno Paiva
Reviews11 Aug 2020
Leukemia

Volume: 35, P: 18-30

Search

Filter By:

Search

Quick links